Petter Björquist
Director/Board Member at PHASE HOLOGRAPHIC IMAGING PHI AB
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jan Anders Holgersson | M | - |
NovaHep AB
 NovaHep AB Miscellaneous Commercial ServicesCommercial Services NovaHep AB provides stem-cell research for gene therapy of liver diseases. Its main area of focus is the development of biological, individualised blood vessels that can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The company was founded by Suchitra Sumitran-Holgersson and Jan Anders Holgersson in 2005 and is headquartered in Gothenburg, Sweden. | 19 years |
| Jan Peter Egelberg | M | 61 | 27 years | |
| Patrik Eschricht | M | 60 | 6 years | |
| Mats Lundwall | M | 76 |
Takara Bio Europe AB
 Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | 18 years |
| Lisa Bodily | F | - | 2 years | |
| Leland George Foster | M | 78 | 12 years | |
| Dana Roy Leach | M | - |
NovaHep AB
NovaHep AB Miscellaneous Commercial ServicesCommercial Services NovaHep AB provides stem-cell research for gene therapy of liver diseases. Its main area of focus is the development of biological, individualised blood vessels that can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The company was founded by Suchitra Sumitran-Holgersson and Jan Anders Holgersson in 2005 and is headquartered in Gothenburg, Sweden. | - |
| Kersti Alm | F | - | - | |
| Ann Christine Egelberg | F | 61 | 20 years | |
| Jonas Bergkvist | M | 53 | 7 years | |
| Birgitta L-Öfverholm | F | - |
NovaHep AB
NovaHep AB Miscellaneous Commercial ServicesCommercial Services NovaHep AB provides stem-cell research for gene therapy of liver diseases. Its main area of focus is the development of biological, individualised blood vessels that can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The company was founded by Suchitra Sumitran-Holgersson and Jan Anders Holgersson in 2005 and is headquartered in Gothenburg, Sweden. | - |
| Jonathan Finn | M | 50 |
Verigraft
 Verigraft BiotechnologyHealth Technology Verigraft engages in the development of personalized human tissues for transplantation. The company is headquartered in Gothenburg, Sweden. | - |
| Mattias Lundin | M | 56 | 4 years | |
| Stefan-Erik von Euw | M | - |
NovaHep AB
NovaHep AB Miscellaneous Commercial ServicesCommercial Services NovaHep AB provides stem-cell research for gene therapy of liver diseases. Its main area of focus is the development of biological, individualised blood vessels that can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The company was founded by Suchitra Sumitran-Holgersson and Jan Anders Holgersson in 2005 and is headquartered in Gothenburg, Sweden. | - |
| Raimund Strehl | M | - |
NovaHep AB
NovaHep AB Miscellaneous Commercial ServicesCommercial Services NovaHep AB provides stem-cell research for gene therapy of liver diseases. Its main area of focus is the development of biological, individualised blood vessels that can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The company was founded by Suchitra Sumitran-Holgersson and Jan Anders Holgersson in 2005 and is headquartered in Gothenburg, Sweden. | - |
| Håkan Rosvall | M | 45 | 14 years | |
| Gyeong Hee Kim | F | 62 |
NovaHep AB
NovaHep AB Miscellaneous Commercial ServicesCommercial Services NovaHep AB provides stem-cell research for gene therapy of liver diseases. Its main area of focus is the development of biological, individualised blood vessels that can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The company was founded by Suchitra Sumitran-Holgersson and Jan Anders Holgersson in 2005 and is headquartered in Gothenburg, Sweden. | - |
| Richard Warburg | M | - |
Verigraft
Verigraft BiotechnologyHealth Technology Verigraft engages in the development of personalized human tissues for transplantation. The company is headquartered in Gothenburg, Sweden. | 5 years |
| Goran Dubravcic | M | 45 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Johan Hyllner | M | 62 |
Takara Bio Europe AB
Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | 12 years |
| Mathieu Simon | M | 68 |
Takara Bio Europe AB
Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Sweden | 21 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Petter Björquist
- Personal Network
